An overview of tuberculosis plant-derived vaccines Review uri icon


  • Tuberculosis (TB) is leading fatal infectious disease to which the current BCG vaccine has questionable efficacy in adults. Thus, the development of improved vaccines against TB is needed. In addition, decreasing the cost of vaccine formulations is required for broader vaccination coverage through global vaccination programs. In this regard, the use of plants as biofactories and delivery vehicles of TB vaccines has been researched over the last decade. These studies are systematically analyzed in the present review and placed in perspective. It is considered that substantial preclinical trials are still required to address improvements in expression levels as well as immunological data. Approaches for testing additional antigenic configurations with higher yields and improved immunogenic properties are also discussed. © 2015 Informa UK, Ltd.

publication date

  • 2015-01-01